financial relationships

What, The RUC, Again? - One of the World's Most Prominent Medica...

Health Care Renewal  Fri, 02/13/2009 - 15:28

With health care reform continuing as a hot topic in the US, more discussions of issues of interest to Health Care Renewal are appearing.

We previously posted about a discussion of how physicians are paid by the US Medicare physician by a prominent expert.

We noted that his discussion seemed to avoid critical issues, and thus may have failed to suggest changes that would address the real problems.


 

A Few Small Steps Towards Better Disclosure of Conflicts of Inte...

Health Care Renewal  Mon, 12/15/2008 - 10:32

Various kinds of conflicts of interest affecting medical academics, practicing physicians, and diverse health care decision makers have frequently been topics of discussion on Health Care Renewal.


 

A List of Unconflicted Experts Produces an Unexpected Response

Health Care Renewal  Thu, 05/15/2008 - 14:14

We previously discussed an article by Jeanne Lenzer and Shannon Brownlee in Slate The article discussed a show broadcast on many US National Public Radio (NPR) stations which portrayed a rather benign view of the side-effects of anti-depressant medications.

Not revealed to listeners was that the show was partially funded by a company that manufacturers such medication, and all the participants in the show had some financial relationships with such companies.


 

BLOGSCAN - Continuing Investigation of Orthopods' Financial Rela...

Health Care Renewal  Tue, 03/25/2008 - 14:49

On the Hooked: Ethics, Medicine and Pharma blog, Dr Howard Brody expanded his focus a bit to include medical device companies.

He posted about the ongoing investigations of orthopedic surgeons' financial relationships to the manufacturers of prosthetic joints.


 

BLOGSCAN - Policy Suggestions Re Physicians and Pharma from "Jac...

Health Care Renewal  Fri, 02/15/2008 - 15:44

On the PharmaGossip blog, "Jack Friday" posted his list of suggestions to the UK Royal College of Physicians working group on relationships among physicians and the pharmaceutical industry.